CLINICAL AND PHARMACOKINETIC PROFILES OF DIGOXIN IMMUNE FAB IN 4 PATIENTS WITH RENAL IMPAIRMENT

被引:16
作者
ALLEN, NM
DUNHAM, GD
SAILSTAD, JM
FINDLAY, JWA
机构
[1] DUKE UNIV,MED CTR,DEPT PHARM,DURHAM,NC 27710
[2] WELLCOME RES LABS,DEPT PHARMACOKINET & DRUG METAB,RES TRIANGLE PK,NC 27709
来源
DICP-THE ANNALS OF PHARMACOTHERAPY | 1991年 / 25卷 / 12期
关键词
D O I
10.1177/106002809102501205
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Minimal pharmacokinetic data on digoxin immune Fab are currently available, especially in patients with impaired renal function. The serum concentration-time profiles of total digoxin, free digoxin, and digoxin immune Fab in four patients with moderate to severe renal impairment who received digoxin immune Fab are presented. The calculated elimination half-life of digoxin immune Fab was 25-73 hours. The calculated elimination half-life of total digoxin was 24-72 hours. Free digoxin concentrations rebounded to a peak of 1-2.9 ng/mL 44-97 hours after the administration of digoxin immune Fab. The areas under the curve for digoxin immune Fab were 213-1026-mu-g.h/mL, and total body clearances were 2.3-7.1 mL/min. The total digoxin concentrations peaked at 14-33 times the pre-Fab digoxin concentrations 5-30 hours after digoxin immune Fab administration. In comparing these data with data available from patients with normal renal function, the half-life of digoxin immune Fab and total digoxin was longer, the peak total digoxin concentration occurred later, the ratio of the peak total digoxin concentration to pre-Fab digoxin concentration was larger, and the rebound in free digoxin occurred later in patients with renal impairment. The Fab dose should not be reduced in patients with renal impairment; however, post-Fab monitoring should be extended to compensate for the prolonged half-life of Fab and later rebound of free digoxin.
引用
收藏
页码:1315 / 1320
页数:6
相关论文
共 18 条
[11]  
SAILSTAD JM, 1990, J CLIN IMMUNOASSAY, V13, P53
[12]   KINETICS OF THE FAB FRAGMENTS OF DIGOXIN ANTIBODIES AND OF BOUND DIGOXIN IN PATIENTS WITH SEVERE DIGOXIN INTOXICATION [J].
SCHAUMANN, W ;
KAUFMANN, B ;
NEUBERT, P ;
SMOLARZ, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (05) :527-533
[13]   KINETICS OF DIGOXIN AND ANTI-DIGOXIN ANTIBODY FRAGMENTS DURING TREATMENT OF DIGOXIN TOXICITY [J].
SINCLAIR, AJ ;
HEWICK, DS ;
JOHNSTON, PC ;
STEVENSON, IH ;
LEMON, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :352-356
[14]   REVERSAL OF ADVANCED DIGOXIN INTOXICATION WITH FAB FRAGMENTS OF DIGOXIN-SPECIFIC ANTIBODIES [J].
SMITH, TW ;
HABER, E ;
YEATMAN, L ;
BUTLER, VP .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (15) :797-800
[15]   DIGOXIN SPECIFIC ANTIBODY (FAB) FRAGMENTS IN 34 CASES OF SEVERE DIGITALIS INTOXICATION [J].
SMOLARZ, A ;
ROESCH, E ;
LENZ, E ;
NEUBERT, H ;
ABSHAGEN, P .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1985, 23 (4-6) :327-340
[16]   TREATMENT OF 63 SEVERELY DIGITALIS-TOXIC PATIENTS WITH DIGOXIN-SPECIFIC ANTIBODY FRAGMENTS [J].
WENGER, TL ;
BUTLER, VP ;
HABER, E ;
SMITH, TW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 5 (05) :A118-A123
[17]  
WENGER TL, 1988, PRIM CARDIOL, P19
[18]  
1987, PACKAGE INSERT DIGOX